Sarah Araji

Dr. Sarah Araji


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2020 in Medicina
Verified
Journal Article
Open access
PDF file
DEDeena Elkafrawi
Deena Elkafrawi
Giovanni SistiGiovanni Sisti
Giovanni Sisti
SASarah Araji
Sarah Araji
AKAldo Khoury
Aldo Khoury
JMJacob Miller
Jacob Miller
BEBrian Rodriguez Echevarria
Brian Rodriguez Echevarria
Background and Objectives: Risk factors for neonatal/maternal morbidity and mortality in placental abruption have been incompletely studied in the current literature. Most of the research overlooked the African American population as mostly Caucasian populations are selected. We aimed to find which risk factor influence the neonatal and maternal outcome in cases of placental abruption occurring in African American pregnant women in an inner-city urban setting. Materials and Methods: We performed a retrospective cohort study at St. Joseph’s Regional Medical Center, NJ United States of America (USA), between 1986 and 1996. Inclusion criteria were African American race, singleton pregnancy with gestational age over 20 weeks and placental abruption. Maternal age, gravidity, parity, gestational age at delivery/occurrence of placental abruption and mode of delivery were collected. Risk factors for placental abruption such as placenta previa, hypertensive disorders of pregnancy, cigarette smoking, crack/cocaine and alcohol use, mechanical trauma, preterm premature rupture of membranes (PPROM), and premature rupture of membranes (PROM) were recorded. Poor neonatal outcome was considered when anyone of the following occurred: 1st and 5th minute Apgar score lower than 7, intrauterine fetal demise (IUFD), perinatal death, and neonatal arterial umbilical cord pH less than 7.15. Poor maternal outcome was considered if any of the following presented at delivery: hemorrhagic shock, disseminated intravascular coagulation (DIC), hysterectomy, postpartum hemorrhage (PPH), maternal intensive care unit (ICU) admission, and maternal death. Results: A population of 271 singleton African American pregnant women was included in the study. Lower gestational age at delivery and cesarean section were statistically significantly correlated with poor neonatal outcomes (p = 0.018; p < 0.001; p = 0.015) in the univariate analysis; only lower gestational age at delivery remained significant in the multivariate analysis (p = < 0.001). Crack/cocaine use was statistically significantly associated with poor maternal outcome (p = 0.033) in the univariate analysis, while in the multivariate analysis, hemolysis, elevated enzymes, low platelet (HELLP) syndrome, crack/cocaine use and previous cesarean section resulted significantly associated with poor maternal outcome (p = 0.029, p = 0.017, p = 0.015, p = 0.047). PROM was associated with better neonatal outcome in the univariate analysis, and preeclampsia was associated with a better maternal outcome in the multivariate analysis. Conclusions: Lower gestational age at delivery is the most important risk factor for poor neonatal outcome in African American women with placental abruption. Poor maternal outcome correlated with HELLP syndrome, crack/cocaine use and previous cesarean section. More research in this understudied population is needed to establish reliable risk factors and coordinate preventive interventions.

29 December 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
MMMona Makhamreh
Mona Makhamreh
KSKavya Shivashankar
Kavya Shivashankar
SASarah Araji
Sarah Araji
ECElizabeth Critchlow
Elizabeth Critchlow
BOBarbara M. O'BRien
Barbara M. O'BRien
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly

27 October 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
ECElizabeth Critchlow
Elizabeth Critchlow
SWSascha Wodoslawsky
Sascha Wodoslawsky
MMMona Makhamreh
Mona Makhamreh
SRStephanie M. Rice
Stephanie M. Rice
OTOzhan Turan
Ozhan Turan
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly

19 September 2025 in Prenatal Diagnosis
Verified
Journal Article
Open access
SASarah Araji
Sarah Araji
OTOnur Turkoglu
Onur Turkoglu
MMMohamad Ali Maktabi
Mohamad Ali Maktabi
TATracy Ashby
Tracy Ashby
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
Fetal congenital anomalies and genetic disorders complicate 3%–5% of pregnancies and can have a significant impact on pregnancy outcomes. Precise and individualized prenatal diagnosis is crucial for effective counseling and management. The identification of new biomarkers holds promise for enhancing prenatal screening, diagnosis, and prognostic counseling in affected pregnancies. Recently, metabolomics has emerged as a potential adjunct in the interpretation of genetic variants identified through genome‐wide sequencing for rare genetic conditions. To assess the potential of metabolomic profiling as a functional assay capable of providing deeper insights into the pathological processes and genetic findings associated with prenatal congenital anomalies, we conducted a comprehensive literature review. We searched MEDLINE (OVID), Embase (Elsevier), Web of Science (Clarivate), and Cochrane Library (Wiley) for relevant studies published through March 2025, focusing on metabolomic profiling of pregnancies affected by fetal structural anomalies or genetic disorders. While metabolomics is a promising tool in prenatal screening and diagnosis, its integration into clinical practice remains limited.

1 January 2025 in AME Case Reports
Verified
Journal Article
Open access
PDF file
ADAlexis M. Dunn
Alexis M. Dunn
LCLaura E. Coats
Laura E. Coats
TJTulip A. Jhaveri
Tulip A. Jhaveri
KBKamir Boodoo
Kamir Boodoo
SWSamantha Williams
Samantha Williams
SASarah Araji
Sarah Araji
Background: Brucella spp., a gram-negative bacterium, is one of the most prevalent zoonotic illnesses worldwide and is more commonly seen in animals; however, the disease may be present in humans. Clinical manifestations of brucellosis are variable and can range from asymptomatic to severe disease. In women who are pregnant, potential obstetrics complications are possible. The purpose of this report is to present a case of brucellosis in a pregnant patient and discuss the potential complications and treatment recommendations. Case Description: We present a case of a 17-year-old gravida 2, parity 1 (G2P1) at 35 weeks and 2 days (35w2d) with brucellosis after she assisted in the delivery of puppies. All puppies were stillborn and the dog was confirmed positive for B. canis on serological testing. Our patient was also found to have B. canis, which is a particularly rare cause of human brucellosis. She was treated with ceftriaxone, rifampin, and gentamicin before delivery and switched to doxycycline and ceftriaxone postpartum until negative. The patient was instructed not to breastfeed. After treatment, the patient felt well and the baby was healthy. Conclusions: When evaluating patients, it is necessary to obtain a social history including animal exposures to rule in or rule out zoonotic infections such as brucellosis. It is important to establish a suspected brucellosis infection in pregnancy and begin antibiotic treatment as soon as possible to prevent maternal and fetal complications. The treatment regimen we administered was an effective strategy, particularly for pregnancy, when typical treatments are contraindicated.

1 May 2023 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
AMAhmed Zaki Moustafa
Ahmed Zaki Moustafa
SASarah Araji
Sarah Araji
NCNatalie Clericuzio
Natalie Clericuzio
DFDanielle Frieson
Danielle Frieson
LHLaura Godfrey Hendon
Laura Godfrey Hendon
INTRODUCTION: Triploidy is a chromosomal abnormality that occurs in 1–3% of all conceptions and often results in early spontaneous miscarriage. It is exceedingly rare for a triploid fetus to survive to birth. Neonates usually die within hours to days after delivery. After the Dobbs v Jackson Women's Health Organization ruling in July 2022, access to abortion is becoming increasingly limited, and therefore providers should consider the adverse maternal health outcomes that can be associated with triploidy. METHODS: In this case series, we describe three cases of confirmed fetal triploidy that we encountered in our center within 1 year (2021–2022). All three cases were referred to us after House Bill 1259 was passed on July 1, 2020, in Mississippi banning termination of pregnancy based on race, sex, or genetic abnormality. RESULTS: Our first case is a 21-year-old patient referred at 19 weeks 2 days for abnormal second-trimester serum screen. Ultrasound showed an enlarged multicystic placenta and multiple fetal anomalies. Amniocentesis showed a 69,XXY karyotype. Patient was managed expectantly. At 21 week 5 days, patient was diagnosed with superimposed preeclampsia with severe features. Patient underwent medical termination of pregnancy. The second case is a 25-year-old referred at 30 weeks 0 days for concerns of fetal anomalies. Ultrasound confirmed multiple fetal anomalies. Amniocentesis showed a 69,XXY karyotype. Patient was diagnosed with preeclampsia and pulmonary edema and was delivered at 30 weeks 1 day. The neonate passed away at 22 days of life. Our third case is a 20-year-old referred at 24 weeks 0 days for abnormal aneuploidy screening. Ultrasound showed a major cardiac defect and severe fetal growth restriction. Amniocentesis showed a 69,XXY karyotype. Patient was managed expectantly. At 29 weeks 0 days, intrauterine fetal demise was diagnosed. Patient was diagnosed with peripartum depression. CONCLUSION: Women with pregnancies affected by fetal triploidy are at risk of developing preeclampsia. Restricting access to abortion will lead to increased maternal morbidity and mortality rates.